A Phase I/II Study of the Immune Checkpoint Inhibitor M7824 and the Immunocytokine M9241 in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Advanced Pancreas Cancer
Conditions: Histologically or Cytologically Confirmed Pancreatic Cancer; Unresectable or Borderline Resectable Pancreatic Cancer; Pancreatic Neoplasms; Pancreatic Cancer; Metastatic Pancreatic Cancer Interventions: Drug: M7824; Drug: M9241; Radiation: SBRT Sponsor: National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Cytology | Pancreas | Pancreatic Cancer | Radiation Therapy | Research | Study